Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Contrasting consequences of podocyte insulin-like growth factor 1 receptor inhibition.
Hurcombe JA, Barrington F, Marchetti M, Betin VMS, Bowen EE, Lay AC, Ni L, Dayalan L, Pope RJP, Brinkkoetter PT, Holzenberger M, Welsh GI, Coward RJM. Hurcombe JA, et al. Among authors: brinkkoetter pt. iScience. 2024 Apr 16;27(5):109749. doi: 10.1016/j.isci.2024.109749. eCollection 2024 May 17. iScience. 2024. PMID: 38706850 Free PMC article.
Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.
Kühne L, Knöbl P, Eller K, Thaler J, Sperr WR, Gleixner K, Osterholt T, Kaufeld J, Menne J, Buxhofer-Ausch V, Mühlfeld A, Seelow E, Schreiber A, Todorova P, Cukoski S, Jabs WJ, Özcan F, Gäckler A, Schönfelder K, Seibert FS, Westhoff T, Schwenger V, Eichenauer DA, Völker LA, Brinkkoetter PT. Kühne L, et al. Among authors: brinkkoetter pt. Blood. 2024 Oct 3;144(14):1486-1495. doi: 10.1182/blood.2023023780. Blood. 2024. PMID: 38838300
Personalized, interdisciplinary patient pathway for cross-sector care of multimorbid patients (eliPfad trial): study protocol for a randomized controlled trial.
Lindemann CH, Burst V, Völker LA, Brähler S, Simic D, Becker I, Hellmich M, Kurscheid C, Scholten N, Krauspe R, Leibel K, Stock S, Brinkkoetter PT. Lindemann CH, et al. Among authors: brinkkoetter pt. Trials. 2024 Mar 11;25(1):177. doi: 10.1186/s13063-024-08026-8. Trials. 2024. PMID: 38468319 Free PMC article.
The podocytes' inflammatory responses in experimental GN are independent of canonical MYD88-dependent toll-like receptor signaling.
Schömig T, Diefenhardt P, Plagmann I, Trinsch B, Merz T, Crispatzu G, Unnersjö-Jess D, Nies J, Pütz D, Sierra Gonzalez C, Schermer B, Benzing T, Brinkkoetter PT, Brähler S. Schömig T, et al. Among authors: brinkkoetter pt. Sci Rep. 2024 Jan 27;14(1):2292. doi: 10.1038/s41598-024-52565-8. Sci Rep. 2024. PMID: 38280906 Free PMC article.
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
Völker LA, Kaufeld J, Balduin G, Merkel L, Kühne L, Eichenauer DA, Osterholt T, Hägele H, Kann M, Grundmann F, Kolbrink B, Schulte K, Gäckler A, Kribben A, Boss K, Potthoff SA, Rump LC, Schmidt T, Mühlfeld AS, Schulmann K, Hermann M, Gaedeke J, Sauerland K, Bramstedt J, Hinkel UP, Miesbach W, Bauer F, Westhoff TH, Bruck H, Buxhofer-Ausch V, Müller TJ, Wendt R, Harth A, Schreiber A, Seelow E, Tölle M, Gohlisch C, Bieringer M, Geuther G, Jabs WJ, Fischereder M, von Bergwelt-Baildon A, Schönermarck U, Knoebl P, Menne J, Brinkkoetter PT; German TTP-Study Group. Völker LA, et al. Among authors: brinkkoetter pt. J Thromb Haemost. 2023 Mar;21(3):559-572. doi: 10.1016/j.jtha.2022.11.010. Epub 2022 Dec 22. J Thromb Haemost. 2023. PMID: 36696206 Free article.
75 results